

Elena Corradini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2144277/publications.pdf>

Version: 2024-02-01

36
papers

2,793
citations

236612

25
h-index

377514

34
g-index

37
all docs

37
docs citations

37
times ranked

2534
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study. <i>American Journal of Gastroenterology</i> , 2022, 117, 147-157.	0.2	39
2	Iron in Porphyrias: Friend or Foe?. <i>Diagnostics</i> , 2022, 12, 272.	1.3	4
3	Can Disruption of Basal Ganglia-Thalamocortical Circuit in Wilson Disease Be Associated with Juvenile Myoclonic Epilepsy Phenotype?. <i>Brain Sciences</i> , 2022, 12, 553.	1.1	2
4	Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. <i>Journal of Hepatology</i> , 2021, 75, 506-513.	1.8	40
5	Reply to: "Ceruloplasmin variants might have different effects in different iron overload disorders". <i>Journal of Hepatology</i> , 2021, 75, 1004-1006.	1.8	2
6	Impact of natural neuromedin B receptor variants on iron metabolism. <i>American Journal of Hematology</i> , 2020, 95, 167-177.	2.0	7
7	Genetic iron overload disorders. <i>Molecular Aspects of Medicine</i> , 2020, 75, 100896.	2.7	28
8	Hyperhomocysteinemia in patients with acute porphyrias: A potentially dangerous metabolic crossroad?. <i>European Journal of Internal Medicine</i> , 2020, 79, 101-107.	1.0	22
9	Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 1325-1334.	1.9	48
10	Clinical impact of application of risk assessment models (Padua Prediction Score and Improve Bleeding) in thromboprophylaxis: a real life prospective and retrospective observational study on patients hospitalized in a Single Internal Medicine Unit (the STIME study). <i>Internal and Emergency Medicine</i> , 2018, 13, 527-534.	1.0	31
11	Subacute copper-deficiency myelopathy in a patient with occult celiac disease. <i>Journal of Spinal Cord Medicine</i> , 2017, 40, 489-491.	0.7	11
12	Gluconeogenic Signals Regulate Iron Homeostasis via Hfe in Mice. <i>Gastroenterology</i> , 2014, 146, 1060-1069.e3.	0.6	111
13	Hepatitis B virus DNA integration in tumour tissue of a non-cirrhotic HFE-haemochromatosis patient with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013, 58, 190-193.	1.8	26
14	Iron and steatohepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 42-46.	1.4	52
15	Iron Regulation of Hfe Despite Attenuated Smad1,5,8 Signaling in Mice Without Transferrin Receptor 2 or Hfe. <i>Gastroenterology</i> , 2011, 141, 1907-1914.	0.6	89
16	Regulation of Tmprss6 by BMP6 and iron in human cells and mice. <i>Blood</i> , 2011, 118, 747-756.	0.6	104
17	Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway in mice. <i>Hepatology</i> , 2011, 54, 273-284.	3.6	169
18	Non-HFE Hepatic Iron Overload. <i>Seminars in Liver Disease</i> , 2011, 31, 302-318.	1.8	90

#	ARTICLE	IF	CITATIONS
19	Hepcidin Expression Does Not Rescue the Iron-Poor Phenotype of Kupffer Cells in Hfe-Null Mice After Liver Transplantation. <i>Gastroenterology</i> , 2010, 139, 315-322.e1.	0.6	26
20	BMP6 Treatment Compensates for the Molecular Defect and Ameliorates Hemochromatosis in Hfe Knockout Mice. <i>Gastroenterology</i> , 2010, 139, 1721-1729.	0.6	99
21	Altered hepatic BMP signaling pathway in human HFE hemochromatosis. <i>Blood Cells, Molecules, and Diseases</i> , 2010, 45, 308-312.	0.6	36
22	BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. <i>Nature Genetics</i> , 2009, 41, 482-487.	9.4	678
23	The RGM/DRAGON family of BMP co-receptors. <i>Cytokine and Growth Factor Reviews</i> , 2009, 20, 389-398.	3.2	102
24	Bone Morphogenetic Protein Signaling Is Impaired in an Hfe Knockout Mouse Model of Hemochromatosis. <i>Gastroenterology</i> , 2009, 137, 1489-1497.	0.6	131
25	Serum Ferritin as a Predictor of Treatment Outcome in Patients With Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2009, 104, 605-616.	0.2	35
26	Method for Measuring Macrophage Iron Efflux in Vitro and in Vivo Using Magnetic Resonance Imaging. <i>Blood</i> , 2008, 112, 4636-4636.	0.6	0
27	Disease progression and liver cancer in the ferroportin disease. <i>Gut</i> , 2007, 56, 1030-1032.	6.1	24
28	STAT3 Is Required for IL-6-gp130-Dependent Activation of Hepcidin In Vivo. <i>Gastroenterology</i> , 2007, 132, 294-300.	0.6	279
29	Magnetic resonance imaging to identify classic and nonclassic forms of ferroportin disease. <i>Blood Cells, Molecules, and Diseases</i> , 2006, 37, 192-196.	0.6	52
30	Hereditary Hemochromatosis. , 2006, , 567-572.		0
31	Molecular and clinical correlates in iron overload associated with mutations in ferroportin. <i>Haematologica</i> , 2006, 91, 1092-5.	1.7	43
32	Kupffer cells and macrophages are not required for hepatic hepcidin activation during iron overload. <i>Hepatology</i> , 2005, 41, 545-552.	3.6	62
33	Lack of enterocyte iron accumulation in the ferroportin disease. <i>Blood Cells, Molecules, and Diseases</i> , 2005, 35, 315-318.	0.6	31
34	Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. <i>Gastroenterology</i> , 2005, 128, 470-479.	0.6	129
35	Iron and the liver. <i>Pediatric Endocrinology Reviews</i> , 2004, 2 Suppl 2, 245-8.	1.2	4
36	Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin) Tj ETQq0 0 0,rgBT /Overlock 10 Tf	0.6	187